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Abstract
Objective To determine the costs and health effects of interventions to
combat breast, cervical, and colorectal cancers in order to guide resource
allocation decisions in developing countries.
Setting Two World Health Organization sub-regions of the world:
countries in sub-Saharan Africa with very high adult and high child
mortality (AfrE); and countries in South East Asia with high adult and
high child mortality (SearD).
Design Cost effectiveness analysis of prevention and treatment
strategies for breast, cervical, and colorectal cancer, using mathematical
modelling based on a lifetime population model.
Data sources Demographic and epidemiological data were taken from
the WHO mortality and global burden of disease databases. Estimates
of intervention coverage, effectiveness, and resource needs were based
on clinical trials, treatment guidelines, and expert opinion. Unit costs
were taken from the WHO-CHOICE price database.
Main outcome measures Cost per disability adjusted life year (DALY)
averted, expressed in international dollars ($Int) for the year 2005.
Results In both regions certain interventions in cervical cancer control
(screening through cervical smear tests or visual inspection with acetic
acid in combination with treatment) and colorectal cancer control
(increasing the coverage of treatment interventions) cost <$Int2000 per
DALY averted and can be considered highly cost effective. In the
sub-Saharan African region screening for colorectal cancer (by
colonoscopy at age 50 in combination with treatment) costs
$Int2000–6000 per DALY averted and can be considered cost effective.
In both regions certain interventions in breast cancer control (treatment
of all cancer stages in combination with mammography screening) cost
$Int2000–6000 per DALY averted and can also be considered cost
effective. Other interventions, such as campaigns to eat more fruit and
vegetable or subsidies in colorectal cancer control, are not cost effective
according to the criteria defined.
Conclusion Highly cost effective interventions to combat cervical and
colorectal cancer are available in the African and Asian sub-regions. In
cervical cancer control, these include screening through smear tests or
visual inspection in combination with treatment. In colorectal cancer,
increasing treatment coverage is highly cost effective (screening through
colonoscopy is cost effective in the African sub-region). In breast cancer
control, mammography screening in combination with treatment of all
stages is cost effective.
Introduction
Malignant neoplasms are responsible for nearly 7.5 million
deaths, representing some 13% of all mortality and 5% of the
globalburdenofdiseaseintermsofdisabilityadjustedlifeyears
(DALYs) lost.
1 Leading contributors to global cancer mortality
include tracheal, bronchial, and lung cancer (18%); stomach
cancer (11%); colorectal cancer (9%); liver cancer (8%); breast
cancer (7%); oesophageal cancer (7%); lymphomas (5%); oral
cancers(5%);prostatecancer(4%);leukaemia(4%);pancreatic
cancer (4%); and cervical cancer (4%).
1
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Research
RESEARCHThis study evaluates a set of 81 interventions (and intervention
combinations)forprevention,screening,andtreatmentofbreast,
cervical,andcolorectalcanceratdifferentgeographiccoverage
levels. The cost effectiveness of interventions against tracheal,
bronchial, and lung cancer in the context of tobacco use is
presented in a companion article in this series.
2 The study does
not evaluate interventions for stomach cancer because of the
absence of known efficacious interventions. Likewise, it does
not evaluate interventions against liver cancer: although
preventive interventions exist, only part of their impact is
captured by reductions in liver cancer (hepatitis B vaccination
has a more direct impact on hepatitis B and cirrhosis, and
interventions to reduce alcohol use are considered within the
context of neuropsychiatric conditions in this series
3).
Breast cancer incidence varies considerably between world
regions, with incidence up to eight times higher in high income
regions than in low income regions such as South Asia.
1
Similarly, colorectal cancer incidence is five to 10 times higher
in high income regions. Conversely, the burden of cervical
cancer is inversely related to economic development, with
300–400 DALYs per million people in high income regions,
rising to 800–1250 in low income regions.
1
This paper provides indications of the cost effectiveness of
prevention, screening, and treatment strategies for reducing the
burden associated with leading causes of cancer in developing
countries.Itdrawsonpreviousanalysesofeachofthecancers,
4-6
here updated to the year 2005 and brought together in order to
elicitinsightsintothecomparativecostsandeffectsofdifferent
intervention strategies across and beyond individual cancer
entities. In common with other studies in this series, we
evaluated interventions for two major global regions using a
standardised analytical approach. The two regions are referred
toassub-SaharanAfrica,includingthoseAfricancountrieswith
very high adult and high child mortality (referred to as AfrE in
the WHO classification) and South East Asia including those
countriesinAsiawithhighadultandhighchildmortality(SearD
in the WHO classification). The use of the standardised
WHO-CHOICE framework allows the comparison of the cost
effectivenessofinterventionswithincancercontrolbutalsothe
comparison of interventions for non-communicable diseases in
general, as presented in this series, and for infant and infectious
diseases as reported earlier.
7
Methods
This section outlines the main principles of WHO-CHOICE
analysis, and its application to the cost effectiveness analysis
of breast, cervical, and colorectal control. Further details on
WHO-CHOICE are presented in detail in the general appendix
on bmj.com and other documents.
8 9 Details on the
disease-specific analysis are reported in appendices 1–3 on
bmj.com.
Intervention effects
WHO-CHOICEemploysanepidemiological,populationbased
approach to the assessment of health outcomes. Along with
background demographic rates, observed rates of cancer
incidence, prevalence, remission, and case fatality (table
1⇓)—primarily drawn from the Global Burden of Disease
database
1—are represented as parameters in a state transition
model in order to establish the total number of years of healthy
life experienced over the lifetime of a defined population (see
general appendix on bmj.com and other documents
8 9). The
model is successively run for each intervention scenario and
compared with the baseline of no interventions for the disease
in question. Thus, the health effects of a range of preventive,
screening, and treatment strategies for cancer are considered,
with effectiveness expressed as a reduction in epidemiological
rates such as incidence or case fatality.
WefollowedstandardWHO-CHOICEmethodsforidentification
of the best available evidence on the (clinical or population)
effectiveness of interventions. In the ideal case, this evidence
is retrieved from systematic reviews, but it is also based on
individualstudiesand,whennoevidenceisavailable,onexpert
opinion. We used evidence on intervention effectiveness
pertaining to the regions under study, or extrapolated this from
Western settings where meaningful. Evaluated interventions
are listed in table 2⇓, and their data sources for intervention
effectiveness are listed in tables 3–5⇓⇓⇓. DALYs averted were
discountedat3%perannumandweightedforage.Interventions
wereanalysedatWHO-CHOICEstandardgeographiccoverage
levels of 50%, 80%, and 95%, referring to the percentage of
eligible cases receiving treatment.
For breast cancer, we evaluated lumpectomy with auxiliary
dissectionsupplementedwithexternalradiotherapytothebreast
for stage I and II cancer; for stage III cancer, we evaluated
neoadjuvant chemotherapy followed by mastectomy with
auxiliarydissectionsupplementedwithadjuvantchemotherapy
including external breast radiotherapy; and for stage IV cancer,
weevaluatedsystemicchemotherapy.Allinterventionsincluded
endocrine therapy for eligible patients. We also considered
combinations of treatment strategies, with and without the
implementation of a breast awareness program and early case
finding through biannual mammography screening in women
aged 50–70 years. Details on assumptions on intervention
effectivenessareprovidedintable3⇓,andthemodellingdesign
is provided in appendix 1 on bmj.com.
For cervical cancer, screening interventions (plus removal of
lesions as required) included the smear test, testing for human
papillomavirus(HPV)DNA,visualinspectionwithaceticacid,
and combinations of smear test with HPV DNA testing at
various frequencies. HPV vaccination in a scenario where a
booster dose is required every 10 years
5 16 assumed an efficacy
of 100% against viral genotypes 16 and 18,
17 which together
accountforaroundtwothirdsofcervicalcancersinlowincome
countries.
18-20 Treatment of cervical cancer included
chemotherapy,radiotherapy,andsurgery.Detailsofassumptions
on intervention effectiveness are provided in table 4⇓, and the
modelling design is provided in appendix 2 on bmj.com.
For colorectal cancer, a range of single screening (at age
50years) and repeated screening (every five or 10 years)
strategies were assessed, including faecal occult blood test,
sigmoidoscopy, colonoscopy, and (despite uncertain evidence
as to its efficacy) digital rectal examination, with subsequent
removal of polyps and cancerous lesions as needed. The
estimated impact of these strategies on the incidence of
colorectal cancer ranged from 2.6% (single screening at age 50
withfaecaloccultbloodtest)toover50%(suchascolonoscopy
every 10 years, annual faecal occult blood test plus
sigmoidoscopyeveryfiveyears).
6Treatmentstrategiesincluded
radiotherapy, chemotherapy, and surgery. In addition, the
preventive effect of a mass media campaign focused on
increasing fruit and vegetable consumption was considered.
Details on assumptions on intervention effectiveness are
provided in table 5⇓, and the modelling design is provided in
appendix 3 on bmj.com.
At present, cancer control strategies in many sub-Saharan
AfricanandSouthEastAsiancountriesmainlyrelyontreatment
of (often) advanced cases in referral hospitals, with treatment
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RESEARCHavailability varying widely in and among countries in the
regions.Atpresent,thereislowtoverylowcoverageofcervical
cancer vaccination or screening programmes in the regions
27:
inSouthAfricacoverageofsmeartestscreeningisaround10%,
whileinIndiaitislessthan1%.
28However,screeningbyvisual
inspection with acetic acid is likely to be more common.
Screening programmes for colorectal or breast cancer
29 are
virtually absent.
Intervention costs
WHO-CHOICE employs an ingredients approach to costing,
suchthatresourcesusedintheimplementationofanintervention
(such as outpatient visits or diagnostic tests) are specified in
detail, and the unit costs of these resources are determined
separately. For example, for the breast cancer analysis, patient
level patterns of resource use (that is, initial evaluation, local
treatment, and follow-up) were based on clinical practice
guidelines,
30 31 and are summarised by Groot et al.
4 Since only
a small proportion of all presenting women are diagnosed with
breast cancer, most of the resources used for initial evaluation
correspond to women diagnosed as not having breast cancer.
Screening in the extensive cancer programme included
mammographic screening of women aged 50–70 years, with
further diagnostic tests on referral. Stage-specific treatment
protocols for treating cervical cancer were based on standard
practice in high income countries.
32 33 Resource quantities for
the delivery of screening tests and treatment procedures for
cervical and colorectal cancer (staff salaries, room use, drugs,
and disposable and reusable equipment) were retrieved from a
SouthAfricandatabase.
34Beyondthesefacilitylevelresources,
estimates of the resources needed to set up and maintain
screening programmes were generated, based on a standard
procedure
35andpredictednumbersofhumanandotherresources
required to implement the programmes (such as four or five
administrative posts per million population for notification,
coordination, follow-up, and monitoring activities
5 6). Details
on resource use patterns are provided in appendices 1–3 on
bmj.com.
Unit costs of non-traded goods—including salaries of health
and administrative workers as well as inpatient and outpatient
services—were retrieved from the WHO-CHOICE database
(www.who.int/choice/costs), which reports region-specific
valuesderivedfromeconometricestimation.
36Drugpriceswere
obtained from the International Drug Price Indicator Guide,
marked up for international and local transportation costs.
37 38
Unitcostsoflaboratory,diagnostic,andscreeningtests,aswell
as surgical procedures, derived on the basis of the
aforementioned South African database, are provided in
appendices 1–3.
Unitcostswerecombinedwithresourceusepatterns(described
in more detail in appendices 1–3) to estimate costs per patient
treated.Totalpatientcostsinthepopulationwerethencalculated
as the cost per patient treated multiplied by the number of
patientstreated(calculatedfromthemodelledannualincidence
of disease multiplied by the coverage level and the proportion
of cases diagnosed and treated in the covered population). All
costs were reported in international dollars ($Int) for year 2005
tofacilitatemoremeaningfulcomparisonsacrossregions($Int1
buys the same quantity of healthcare resources in the
sub-Saharan African and South East Asian regions as it does in
the United States). Cost estimates in sub-Saharan Africa in
international dollars should be divided by a factor 2.3 to obtain
US dollar cost estimates for Kenya (in South East Asia cost
estimates should be divided by a factor of 3.1 to obtain US$
cost estimates for India).
8 All costs and effects are discounted
at 3%, following standardised WHO-CHOICE analysis.
9
Cost effectiveness
Dividing total implementation costs of each intervention by its
effects generates a simple average cost effectiveness ratio
relativetoacomparatorsituationofnointervention.Inaddition,
incremental cost effectiveness ratios are reported for the
successive set of interventions that would be selected at
expanding levels of resource availability, starting with the
intervention with the lowest cost per DALY averted, then
movingtothenextmostcosteffectivecombinationintervention
out of the remaining available set of interventions. An
interventionthatismorecostlyorlesseffectivethanothermore
efficient interventions is denoted as “dominated.”
Uncertainty
Estimating the cost effectiveness of interventions is inherently
uncertain. To deal with this, we plot results on a double
logarithmic scale, so as to ascertain order of magnitude
differences (such as $Int10–100 v $Int100–1000 per DALY
averted). Second, we classify results according to defined cost
effectiveness thresholds: WHO-CHOICE calls an intervention
yielding a healthy year of life for less than three times gross
domestic product (GDP) per capita “cost effective,” and an
interventionyieldingahealthyyearoflifeforlessthantheGDP
per capita “very cost effective.” In the sub-regions considered
here an intervention yielding a DALY for <$Int2000 is
consideredhighlycosteffective.InterventionsyieldingaDALY
at a cost greater than three times GDP per capita (>$Int6000)
are considered not cost effective, while those with a cost
effectiveness ratio falling between $Int2000 and $Int6000 are
considered cost effective.
39 Finally, for the subset of
interventions that are not dominated and therefore fall on the
cost effectiveness frontier, we undertook a probabilistic
uncertainty analysis using the MCLeague software program.
40
We also assessed the impact of removing age weights or
discounting on baseline results via one way sensitivity analysis
for interventions with 95% coverage.
Results
Cost, effects, and cost effectiveness of interventions are listed
in tables 6⇓ and 7⇓ for sub-Saharan Africa and South East Asia
and are rank ordered on the basis of their incremental cost
effectiveness ratios (the tables do not include dominated
interventions that are more costly or less effective than other
interventions). The focus here is on determining the most
efficient set of interventions, first within and then across the
disease specific groups (costs, effects, and cost effectiveness of
all interventions are listed in appendices 4–6 on bmj.com for
cervical, colorectal and breast cancer respectively).
In both regions, certain interventions in cervical cancer control
(that is, screening with smear testing or visual inspection with
aceticacidincombinationwithtreatment)andcolorectalcancer
control(increasingthecoverageoftreatmentinterventions)cost
<$Int2000perDALYavertedandcanthusbeconsideredhighly
costeffective.IntheAfricansub-region,screeningforcolorectal
cancer(bycolonoscopyatage50incombinationwithtreatment)
costs <$Int6000 per DALY averted and can be considered cost
effective. In both regions, certain interventions in breast cancer
control (treatment of all stages in combination with
mammographyscreening)costbetween$Int2000and$Int6000
per DALY averted and can be considered cost effective. Below
we discuss the findings in detail.
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RESEARCHIn breast cancer control, treatment of all stages in combination
withmammographyscreeningcosts$Int2248–4596perDALY
averted in both regions. At an optimal coverage level of 95%,
this optimal programme would avert 381 and 595 DALYs per
million population in South East Asia and sub-Saharan Africa
respectively, at a cost of between $Int1.38 and $Int1.68 per
capita(thatis,aroundUS$0.45–0.55).Inbothregionstreatment
of stage I cancer costs between $Int3800 and $Int4548 per
DALYaverted,whereastreatmentofstageIVcosts>$Int49 000
per DALY averted and is the least cost effective option (these
interventions are less effective or more costly than other
combination in breast cancer control and are therefore not
reported in tables 6⇓ and 7⇓).
For cervical cancer, screening 50% of the target population
through a single smear test at age 40, with lesion removal and
treatment as required, represents the single most cost effective
strategy in both sub-Saharan Africa and South East Asia
($Int307 and $Int142 per DALY averted respectively). In both
regions, the next most cost effective intervention is treatment
of invasive cancer with an appropriate combination of surgery,
chemotherapy, and radiotherapy. In both regions, screening by
means of visual inspection with acetic acid instead of the smear
testisslightlymoreeffectivebutalsomorecostly,andtherefore
less cost effective. In sub-Saharan Africa adding an HPV
vaccination programme to the provision of smear tests at age
40 and treatment as required can be considered very cost
effective if a cost per dose of US$0.60 can be realised. In the
South East Asia, an HPV vaccination programme is not cost
effective even at the same low vaccine price. Adding a booster
vaccination every 10 years in addition to such strategies has a
negligibleimpactonhealthoutcomesbutsubstantiallyincreases
costs and hence incremental cost effectiveness values.
In colorectal cancer control, the most cost effective strategy is
the increased coverage of treatment interventions: at 95%
coverage, this would avert 792 and 868 DALYs per million
peopleinSouthEastAsiaandsub-SaharanAfricarespectively,
at a cost of around $Int0.30 per capita in both regions (that is,
around US$0.10). Once treatment has been scaled up, it would
still be cost effective to introduce colonoscopy screening at age
50 in sub-Saharan Africa. The incremental cost and cost
effectiveness of all other assessed interventions makes them
much less attractive options.
The incremental cost and cost effectiveness of these
interventions are shown in figures 1⇓ and 2⇓, which include
only interventions considered cost effective (with a cost
<$Int6000 per DALY averted). These graphs reveal the cost
implications of adding successively less cost effective or more
comprehensive interventions, showing, for example, that the
cumulative cost per capita associated with the provision of one
of the more cost effective interventions for each of the three
cancers is less than $Int1 in both regions.
The probabilistic uncertainty analysis depicted in figures 3⇓
and 4⇓ shows the impact of plausible variations in total costs
and total effects and shows that the average cost effectiveness
ratio of most interventions would retain their classification of
highly cost effective or cost effective, after taking into account
suchuncertainty.Asimilarlogicwouldapplytotheincremental
costeffectivenessratios.Onewaysensitivityanalysis(appendix
7 on bmj.com) shows that, for both sub-regions and all three
diseases, removing age weights in the calculation of DALYs
has a moderate impact on cost effectiveness (cost effectiveness
ratio rising slightly or falling by up to 20%). Removing
discounting as well as age weighting had a far larger influence,
increasing health outcomes and thereby lowering (improving)
cost effectiveness values markedly (by 45–90%).
In addition, we performed a sensitivity analysis on the price of
HPVvaccines:theapproximatethresholdpriceforHPVvaccine
to become very cost effective is US$6 in sub-Saharan Africa
andUS$9inSouthEastAsia.Ifboosterdosesarerequiredevery
10 years, a cost as low as US$1.30 in sub-Saharan Africa and
US$0.90inSouthEastAsiaisrequiredtorendertheintervention
cost effective (data not shown).
Discussion
Principal findings
Our analyses suggest that several highly cost effective
interventions to combat cervical and colorectal cancer are
available in sub-Saharan Africa and South East Asia. For
cervical cancer, these include screening through smear testing
or visual inspection with acetic acid in combination with
treatment. For colorectal cancer, increasing treatment coverage
is highly cost effective (screening through colonoscopy is cost
effective in the African sub-region). For breast cancer,
mammography screening in combination with treatment of all
cancer stages is cost effective.
Policy implications
For breast cancer control, our analyses show that treating early
stagebreastcancerismorecosteffectivethantreatinglatestage
disease.Resultsindicatethatprioritiesinnationalbreastcancer
controlshouldbetheimplementationofanextensiveprogramme
including active mammography screening and treatment of all
stages. Although such a programme reflects the economic
attractiveness of diagnosing breast cancer at an earlier stage,
many developing countries may not be able to meet its total
costs (including the required infrastructure, logistics, and
expertise). Given the limited available resources, priorities are
probably best directed at treatment of early stage disease and
at developing a less expensive means of early diagnosis. We
did not evaluate clinical breast examination or breast self
examination because currently there is no consensus on their
value, either alone or in addition to mammography. However,
together with other ways of raising awareness, they could be
cost effective means by which to diagnose breast cancer earlier
in resource poor settings.
For cervical cancer control, an increased coverage of treatment
servicesandlowcostscreeningprogrammessuchaswithsmear
testing or visual inspection with acetic acid are both
economically very attractive in both regions. Increasing
treatment coverage is challenging and requires ample
investments in hospital infrastructure (especially in rural areas)
and the training of staff in surgery, chemotherapy, and
radiotherapy. Also the implementation of screening through
smear tests is complex and requires routine availability of
laboratoryfacilities.Inthatrespect,implementationofscreening
by means of visual inspection with acetic acid, which does not
require laboratory facilities, may be less complex.
In sub-Saharan Africa an HPV vaccination programme could
alsobeconsideredifvaccinepriceswerelow.However,analyses
of the effect of HPV vaccination have a greater level of
uncertainty
41 42: for example, there is no observational evidence
on the duration of efficacy (conservatively assumed to be 10
years in our analysis), and the price is unknown. We assumed
a vaccine price as low as US$0.60, based on a figure twice that
of the current yellow fever vaccine and the precedent of falling
costs of hepatitis B vaccine in the 1990s. At the current price
(US$40–100perdoseindevelopedcountries),theHPVvaccine
may not necessarily be cost effective in developed, let alone in
developing,countries.Anadditionalquestionistheacceptability
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RESEARCHof vaccination to prevent cervical cancer initially aimed at 12
year old girls, especially in religious cultures.
43 However, it
should be noted that the reported cost effectiveness ratios for
HPVvaccinationareupwardlybiasedinthesensethatourmodel
didnottakeintoaccounttheburdenofcondyloma
44orrecurrent
respiratorypapillomatosis
45onhealthsystems,northepotential
cost savings or DALY reductions when a quadravalent vaccine
isused.
46 47Targetingscreeningandvaccinationstowardspeople
infected with HIV could improve cost effectiveness, since HIV
infection is associated with elevated risk of cervical cancer.
48
A more sensitive but less specific HPV test (carelHPV) will
soon be available in developing countries at a far lower cost
than the Hybrid Capture II test
49. This is likely to improve the
cost effectiveness of HPV DNA testing.
For colorectal cancer control, increasing the low level of
treatment coverage is the most cost effective intervention in
both the regions considered here. Screening by colonoscopy at
age 50 in combination with treatment is also cost effective in
sub-Saharan Africa. The use of digital rectal examination is not
cost effective despite its low cost, as only a small percentage
ofpolypscanbedetected.However,thecosteffectivenessratio
of digital rectal examination is overestimated as our model did
not include the potential effects of reducing mortality from
prostate cancer. We also evaluated the introduction of a
campaigntoencourageconsumptionoffruitandvegetablesand
the provision of price subsidies for fruit and vegetables, but
these are able to avert only a modest level of disease burden
and are accordingly not cost effective in relation to their effect
on colorectal cancer alone. However, such campaigns might be
costeffectivewhenpossibleprotectiveeffectsonotherdiseases
are taken into account.
Comparison with other studies
Several studies have reported on the global and regional cost
effectiveness of interventions targeting breast, cervical, and
colorectal cancer.
4-6 However, these have been carried out in
isolation, which prevents direct comparison of the cost
effectiveness of the different interventions in cancer control. In
addition, these studies were analysed using year 2000
demographics and price levels. Our study directly compares
cost and effects of interventions targeting breast, cervical, and
colorectal cancer using more recent prices. This allows the
identification of most efficient strategies to improve cancer
control in the regions considered. For example, our analyses
showthatcertaininterventionsincervicalcancerandcolorectal
cancer control are more cost effective than others in breast
cancer control in both the considered regions .
Strengths and limitations of study
Aswellasthelimitationsofthesecancer-specificmodels,some
more general shortcomings need to be mentioned. Firstly, our
analysis considers costs and effectiveness of interventions, but
itdoesnotaddresshealthsystemsconstraintsthatadddifficulties
to the actual implementation of the interventions. For cancer
control strategies, constraints may be in terms of infrastructure,
logistics, and expertise, and these factors should be taken into
account when making actual decisions about control strategies.
For example, the expansion of colonoscopy services for
colorectalcancercontrolormammographyscreeningforbreast
cancercontrolwillbeconstrainedbylackoftrainedhealthstaff.
Likewise, the successful implementation of cervical smear
testing and screening for HPV DNA will depend on laboratory
capacity. Also, issues of acceptability may play a role—such
as of the HPV vaccine.
50 We therefore stress that cost
effectiveness analysis should be considered as only one input
in the decision making process and should not be used in a
formulaic way.
Secondly,forsomeinterventions,assumptionsoneffectiveness
were based on studies in other (high income) settings (many
under trial conditions) in the absence of local evidence. This
may overestimate the effectiveness that can be achieved in the
regions of analysis, and therefore the economic attractiveness
of interventions. However, our uncertainty analysis indicates
thatstudyresultsarerobusttoalternativeassumptions.Thirdly,
and closely related, patterns of resource use were sometimes
based on clinical practice guidelines in Western settings—such
as in the cost analysis of breast cancer treatment. The relevance
of these guidelines was then carefully assessed and adjusted
where necessary (see Groot et al
4 for more detail).
Fourthly,wedidnotevaluateallpossibleinterventionsincancer
control, and our selection of interventions for analysis was
pragmatic and somewhat arbitrary. Policy makers should be
aware of this, and should not limit their choice of interventions
to those included in this analysis. Fifthly, the analyses did not
include economies of scale resulting from the joint provision
ofbreast,cervical,orcolorectalcancerinterventions.Inreality,
cost savings may be realised when breast and cervical cancer
screening are jointly organised. Sixthly, in the absence of
reliable data, the analyses did not include time and travel costs
ofpatientsseekingorundergoingcare,nordiditincludechanges
in productivity as a result of the interventions.
51-53 Seventhly,
the analysis evaluates interventions at 50%, 80%, and 95%
geographiccoveragelevels,followingstandardWHO-CHOICE
methodology.Thehighercoveragelevelsmaynotbeachievable
in the short term but are included to indicate the long term
efficiency resulting from economies of scale as more people
are reached.
54 Lastly, analyses are carried out at the regional
level, but important differences in costs and effectiveness of
interventions may exist between countries in the same region.
Since decision making is made at the country (as opposed to
regional)level,morerefinedestimatesofcosts,effects,andcost
effectiveness should be made at the county level, based on
country-specific data. A good example is the contextualisation
of WHO-CHOICE regional results to the country level in
Mexico, as reported in this series.
55
The above limitations should be considered in the overall aim
of WHO-CHOICE analysis to provide broad indications—that
is, a crude, bird’s eye view on the cost effectiveness of a range
of interventions—to inform general policy discussions rather
than to deliver precise estimates on a specific intervention.
7-9
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RESEARCHWhat is already known on this topic
Several studies have reported on the global and regional cost effectiveness of interventions targeting breast, cervical, and colorectal
cancer
These studies have been carried out in isolation, preventing direct comparison of the cost effectiveness of the different interventions
In addition, these studies have been analysed using year 2000 demographics and price levels
What this study adds
This study directly compares, using standardised methodology, cost and effects of interventions targeting breast, cervical, and colorectal
cancer using more recent price levels
Analyses show that several highly cost effective interventions to combat cervical and colorectal cancer are available in sub-Saharan
Africa and South East Asia, including screening for cervical cancer through smear testing or visual inspection with acetic acid in
combination with treatment, and increasing treatment coverage for colorectal cancer (screening through colonoscopy is also cost effective
in the African sub-region)
For breast cancer control, mammography screening in combination with treatment of all stages is cost effective
JAL is a staff member of the WHO. The authors alone are responsible
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RESEARCHTables
Table 1| Epidemiology of breast, cervical, and colorectal cancer in WHO sub-Saharan African sub-region AfrE and South East Asian
sub-region SearD*
South-East Asian region Sear-D African region Afr-E
Age group (years)
Colorectal cancer
Cervical cancer
(women)
Breast cancer
(women)
Colorectal cancer
Cervical cancer
(women)
Breast cancer
(women) Women Men Women Men
Incidence (per 1000 population)
0.00 0.01 0.18 0.01 0.00 0.02 0.23 0.02 15–29
0.02 0.02 0.12 0.21 0.04 0.05 0.27 0.38 30–44
0.09 0.12 0.75 0.45 0.20 0.31 1.58 0.82 45–59
0.23 0.35 1.21 0.79 0.49 0.91 3.46 1.79 60–69
0.30 0.42 0.99 0.95 0.83 1.59 3.95 2.44 70–79
0.89 0.83 1.61 2.18 1.61 3.36 3.56 3.01 ≥80
Prevalence (per 1000 population)
0.11 0.11 8.44 0.18 0.02 0.07 0.08 0.07 15–29
0.43 0.24 3.29 2.40 0.12 0.20 0.76 1.44 30–44
0.87 0.81 11.00 3.43 0.45 0.89 3.83 3.03 45–59
1.46 2.14 9.32 3.48 1.55 3.50 7.45 6.43 60–69
1.15 1.40 2.85 2.28 2.08 5.16 5.72 7.60 70–79
1.68 1.50 2.63 3.58 3.48 9.48 4.26 8.60 ≥80
Mortality (per 1000 population)
0.00 0.00 0.03 0.00 0.00 0.01 0.05 0.01 15–29
0.01 0.02 0.04 0.07 0.02 0.05 0.09 0.13 30–44
0.03 0.04 0.33 0.28 0.07 0.13 0.69 0.47 45–59
0.12 0.20 0.84 0.65 0.26 0.41 2.27 1.26 60–69
0.21 0.32 1.93 0.85 0.58 1.23 3.61 2.04 70–79
0.80 0.78 1.61 2.18 1.44 3.20 3.55 3.01 ≥80
*Data source: WHO Global Burden of Disease.
1
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RESEARCHTable 2| Evaluated interventions for breast, cervical, and colorectal cancer control in WHO sub-Saharan African sub-region AfrE and South
East Asian sub-region SearD. All interventions were evaluated at 50%, 80%, and 95% coverage
Abbreviation Intervention
Breast cancer
Stage I treatment 1: Stage I treatment (Lumpectomy with auxiliary dissection supplemented with external radiotherapy to
breast. Eligible patients also receive endocrine therapy)
Stage II treatment 2: Stage II treatment (Lumpectomy with auxiliary dissection supplemented with external radiotherapy to
breast. Eligible patients also receive endocrine therapy)
Stage III treatment 3: Stage III treatment (neo-adjuvant chemotherapy followed by mastectomy with auxiliary dissection
supplemented with adjuvant chemotherapy. External radiotherapy to the breast. Eligible patients receive
endocrine therapy)
Stage IV treatment 4: Stage IV treatment (systemic chemotherapy supplemented with endocrine therapy for eligible patients)
Combination treatment 5: Combination treatment (treatment of all stages)
Optimal programme 6: Optimal programme (treatment of all stages plus biannual mammographic screening in women aged
50–70 years)
Colorectal cancer
FOB1 1: Annual faecal occult blood tests
FOB2 2: Biennial faecal occult blood tests
SIG5 3: Sigmoidoscopy every 5 years
COL10 4: Colonoscopy every 10 years
FOB1SIG5 5: Annual faecal occult blood test + sigmoidoscopy every 5 years
FOB50 6: Faecal occult blood test at age 50 years
SIG50 7: Sigmoidoscopy at age 50
COL50 8: Colonoscopy at age 50
FOBSIG50 9: Faecal occult blood test + sigmoidoscopy at age 50
RX 10: Medical treatment of cancers
FOB1RX 11: Annual faecal occult blood tests + medical treatment
FOB2RX 12: Biennial faecal occult blood tests + medical treatment
SIG5RX 13: Sigmoidoscopy every 5 years + medical treatment
COL10RX 14: Colonoscopy every 10 years + medical treatment
FOB1SIG5RX 15: Annual faecal occult blood test + sigmoidoscopy every 5 years + medical treatment
FOB50RX 16: Faecal occult blood test at age 50 + medical treatment
SIG50RX 17: Sigmoidoscopy at age 50 + medical treatment
COL50RX 18: Colonoscopy at age 50 + medical treatment
FOBSIG50RX 19: Faecal occult blood test + sigmoidoscopy at age 50 + medical treatment
FVCAMP 20: Fruit and vegetables campaign
FVCAMPRX 21: Fruit and vegetables campaign + medical treatment
DRE1 22: Annual digital rectal examination
DRE1RX 23: Annual digital rectal examination + medical treatment
Cervical cancer
Pap (1,20,65)* 1: Annual screening by cervical smear test for ages 20–65 years (with removal of lesions)
Pap (3,20,65)* 2: Triennial screening by cervical smear test for ages 20–65 (with removal of lesions)
VIA (40)* 3: Screening by visual inspection with acetic acid at age 40 years (with removal of lesions)
Rx 4: Treatment of invasive cancer (including chemotherapy, radiotherapy, and/or surgery)
Pap (1,20,65)* + Rx 5: Annual smear test for ages 20–65 years + cancer treatment
Pap (3,20,65)* + Rx 6: Triennial smear test for ages 20–65 years + cancer treatment
VIA (40)* + Rx 7: Visual inspection with acetic acid at age 40 + cancer treatment
Pap (5,20,65)* 8: Screening by smear test every five years for ages 20–65 (with removal of lesions)
Pap (5,20,65)* + Rx 9: Smear test every five years for ages 20–65 + cancer treatment
Pap (1,20,30) then Pap & HPV (1,30,65)
10: Annual screening by smear test for ages 20–30 years, then annual smear test with HPV vaccination
for ages 30–65 years
Pap (1,20,30) then Pap & HPV (1,30,65) + Rx
11: Annual smear test for ages 20–30 then annual smear test with HPV vaccination for ages 30–65 +
cancer treatment
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RESEARCHTable 2 (continued)
Abbreviation Intervention
Pap (3,20,30) then Pap & HPV (3,30,65) 12: Triennial smear test for ages 20–30 then triennial smear test with HPV vaccination for ages 30–65
Pap (3,20,30) then Pap & HPV (3,30,65) + Rx
13: Triennial smear test for ages 20–30 then triennial smear test with HPV vaccination for ages 30–65 +
cancer treatment
Pap (5,20,30) then Pap & HPV (5,30,65)
14: Smear test every five years for ages 20–30 then smear test with HPV vaccination every five years for
ages 30–65
Pap (5,20,30) then Pap & HPV (5,30,65) + Rx
15: Smear test every five years for ages 20–30 then smear test with HPV vaccination every five years for
ages 30–65 + cancer treatment
Pap (35,40,45)*. 16: Screening by smear test at ages 35, 40, and 45 years (with removal of lesions)
Pap (35,40,45)* + Rx. 17: Smear test at ages 35, 40, and 45 + cancer treatment
HPV (35,40,45) *. 18: HPV vaccination at ages 35, 40, and 45 years (with removal of lesions)
HPV (35,40,45) * + Rx 19: HPV vaccination at ages 35, 40, and 45 + cancer treatment
VIA (35,40,45) 20: Screening by visual inspection with acetic acid at ages 35, 40, and 45 years
VIA (35,40,45) * + Rx 21: Visual inspection with acetic acid at ages 35, 40, and 45 + cancer treatment
Pap (40) * 22: Screening by smear test at age 40 years (with removal of lesions)
Pap (40) * + Rx 23: Smear test at age 40 + cancer treatment
HPV (40) * 24: HPV vaccination at age 40 (with removal of lesions)
HPV (40) * + Rx 25: HPV vaccination at age 40 + cancer treatment
HPVAC(12), $0.60/dose 26: HPV vaccinations starting at age 12 at cost of US$0.60 per vaccine
HPVAC (12), $0.60/dose + Rx 27: HPV vaccinations starting at age 12 at US$0.60 + cancer treatment
HPVAC (12), $2.00/dose 28: HPV vaccinations starting at age 12 at cost of US$2.00 per vaccine
HPVAC (12), $2.00/dose + Rx 29: HPV vaccinations starting at age 12 at US$2.00 + cancer treatment
Pap(1,20,65)*+HPVAC (12,$.60) 30: Annual smear test for ages 20–65 years + HPV vaccinations starting at age 12 at cost US$0.60
Pap(3,20,65)*+HPVAC (12,$.60) 31: Triennial smear test for ages 20–65 years + HPV vaccinations starting at age 12 at cost US$0.60
VIA(40)*+HPVAC (12), $.60) 32: Visual inspection with acetic acid at age 40 + HPV vaccinations starting at age 12 at cost US$0.60
Pap(1,20,65)*+HPVAC (12, $.60) + Rx
33: Annual smear test for ages 20–65 years + HPV vaccinations starting at age 12 at cost US$0.60 +
cancer treatment
VIA(40)*+HPVAC (12, $.60) + Rx
34: Visual inspection with acetic acid at age 40 + HPV vaccinations starting at age 12 at cost US$0.60 +
cancer treatment
Pap(5,20,65)*+HPVAC (12, $.60) 35: Smear test every five years for ages 20–65 + HPV vaccinations starting at age 12 at cost US$0.60
Pap(5,20,65)*+HPVAC (12, $.60) + Rx
36: Smear test every five years for ages 20–65 + HPV vaccinations starting at age 12 at cost US$0.60 +
cancer treatment
Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,$.60)
37: Annual smear test for ages 20–30 then annual smear test with HPV vaccination for ages 30–65 + HPV
vaccinations starting at age 12 at cost US$0.60
Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC
(12,$.60)+Rx
38: Annual smear test for ages 20–30 then annual smear test with HPV vaccination for ages 30–65 + HPV
vaccinations starting at age 12 at cost US$0.60 + cancer treatment
Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,$.60)
39: Triennial smear test for ages 20–30 then triennial smear test with HPV vaccination for ages 30–65 +
HPV vaccinations starting at age 12 at cost US$0.60
Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC
(12,$.60)+Rx
40: Triennial smear test for ages 20–30 then triennial smear test with HPV vaccination for ages 30–65 +
HPV vaccinations starting at age 12 at cost US$0.60 + cancer treatment
Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,$.60)
41: Smear test every five years for ages 20–30 then smear test with HPV vaccination every five years for
ages 30–65 + HPV vaccinations starting at age 12 at cost US$0.60
Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC
(12,$.60)+Rx
42: Smear test every five years for ages 20–30 then smear test with HPV vaccination every five years for
ages 30–65 + HPV vaccinations starting at age 12 at cost US$0.60 + cancer treatment
Pap (35,40,45)* +HPVAC (12,$.60) 43: Smear test at ages 35, 40, and 45 + HPV vaccinations starting at age 12 at cost US$0.60
Pap (35,40,45)* +HPVAC (12,$.60)+Rx
44: Smear test at ages 35, 40, and 45 + HPV vaccinations starting at age 12 at cost US$0.60 + cancer
treatment
HPV (35,40,45)* +HPVAC (12,$.60) 45: HPV vaccination at ages 35, 40, and 45 + HPV vaccinations starting at age 12 at cost US$0.60
HPV (35,40,45)* +HPVAC (12,$.60)+Rx
46: HPV vaccination at ages 35, 40, and 45 + HPV vaccinations starting at age 12 at cost US$0.60 + cancer
treatment
VIA (35,40,45)* +HPVAC (12,$.60)
47: Visual inspection with acetic acid at ages 35, 40, and 45 + HPV vaccinations starting at age 12 at cost
US$0.60
VIA (35,40,45)* +HPVAC (12,$.60)+Rx
48: Visual inspection with acetic acid at ages 35, 40, and 45 + HPV vaccinations starting at age 12 at cost
US$0.60 + cancer treatment
Pap (40)* +HPVAC (12,$.60) 49: Smear test at age 40 + HPV vaccinations starting at age 12 at cost US$0.60
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RESEARCHTable 2 (continued)
Abbreviation Intervention
Pap (40)* +HPVAC (12,$.60)+Rx 50: Smear test at age 40 + HPV vaccinations starting at age 12 at cost US$0.60 + cancer treatment
HPV (40)* +HPVAC (12,$.60) 51: HPV vaccination at age 40 + HPV vaccinations starting at age 12 at cost US$0.60
HPV (40)* +HPVAC (12,$.60)+Rx 52: HPV vaccination at age 40 + HPV vaccinations starting at age 12 at cost US$0.60 + cancer treatment
HPV= human papillomavirus.
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RESEARCHTable 3| Model inputs for cost effectiveness analysis of breast cancer control in WHO sub-Saharan African sub-region AfrE and South East
Asian sub-region SearD
Data source Assumption Variable
Sankaranarayanan et al
10* Distribution of prevalent cases (2005) and incident cases (2005–14)
without breast cancer control programme:
9.4% Stage I
14.2% Stage II
58.0% Stage III
18.4% Stage IV
Bland et al
11† Distribution of incident cases (2005–14) in presence of optimal
breast cancer programme:
49.0% Stage I
37.4% Stage II
8.6% Stage III
5.0% Stage IV
Sankaranarayanan et al
10* Case fatality rate of untreated patients (2005–14):
0.020 Stage I
0.063 Stage II
0.150 Stage III
0.300 Stage IV
Bland et al
11† Case fatality rate of treated patients (2005–14):
0.006 Stage I
0.042 Stage II
0.093 Stage III
0.275 Stage IV
Murray and Lopez
12; Norum et al
13; Launois
et al
14; de Koning et al
15‡
Disability weight:
0.068 Stage I
0.070 Stage II
0.072 Stage III
0.073 Stage IV treated
*Combined data on breast cancer survival and disease staging from studies in Bombay, Bangalore, Barshi, Madras, Rizal, Chiang Mai, and Khon Kaen. These
data, collected at International Agency for Research on Cancer (IARC), give the best available overview of survival and cancer stage distributions in Asian countries.
Because of lack of similar data in sub-Saharan Africa, we assumed the IARC data to represent this region as well. These data represent the absence of breast
cancer control strategies.
†Data on breast cancer survival and disease staging based on a large sample size and specific per treatment. These data represent the presence of an optimal
breast cancer control programme.
‡Health state valuation were based on the Burden of Disease study following standard WHO-CHOICE methods. Since only a single health state valuation is
available for breast cancer, other studies were used to develop health state valuations for each cancer stage. The referred studies are the only studies that
differentiate health state valuations for breast cancer by stage.
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RESEARCHTable 4| Model inputs for cost effectiveness analysis cervical colorectal cancer control in WHO sub-Saharan African sub-region AfrE and
South East Asian sub-region SearD
Data source Assumption Variable
Kim et al
17 100% Efficacy of HPV vaccination against HPV genotypes 16 and 18
Goldie et al
21 Cervical smear test:
0.60 Sensitivity of detecting low grade lesions
0.95 Specificity of detecting low grade lesions
Goldie et al
21 HPV DNA testing:
0.84 Sensitivity of detecting low grade lesions
0.88 Specificity of detecting low grade lesions
Goldie et al
21 Visual inspection with acid (VIA):
0.68 Sensitivity of detecting low grade lesions
0.85 Specificity of detecting low grade lesions
Kim et al
22 Cervical smear + HPV DNA tests combined:
0.94 Sensitivity of detecting low grade lesions
0.93 Specificity of detecting low grade lesions
Murray and Lopez
12 0.075 Disability weight for cervical cancer
HPV= human papillomavirus
Estimates of incidence and case fatality reductions derived from modelling the above data are listed in table A3.1 in appendix 3 on bmj.com.
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RESEARCHTable 5| Model inputs for cost effectiveness analysis of colorectal cancer control in WHO sub-Saharan African sub-region AfrE and South
East Asian sub-region SearD
Data source Assumption Variable
Wagner et al
23* Faecal occult blood test:
0.1 Sensitivity for detecting polyps
0.9 Specificity for detecting polyps
0.6 Sensitivity for detecting cancer
0.9 Specificity for detecting cancer
Wagner et al
23* Sigmoidoscopy:
0.4 Sensitivity for detecting polyps and cancers
0.9 Specificity for detecting polyps and cancers
Wagner et al
23* Colonoscopy:
0.9 Sensitivity for detecting polyps and cancers
1.0 Specificity for detecting polyps and cancers
Herrinton et al
24† Digital rectal examination:
0.04 Sensitivity for detecting polyps and cancers
1.0 Specificity for detecting polyps and cancers
Eat more fruit and vegetables campaign:
Dixon et al
25‡ 12.4% Increased consumption
Lock et al
26§ 0.01 Decrease in cancer risk per 80 mg increase
Murray and Lopez
12¶ Disability weights for colorectal cancer:
0.80 Diagnosis and treatment
0.80 Watchful waiting
0.25 Metathesis
0.19 Terminal
Estimates of incidence and case fatality reductions were derived from modelling the above data and are listed in table A3.1 in appendix 3 on bmj.com.
*Consensus values from systematic literature reviews for the US Office of Technology Assessment.
†Highest available level of evidence, from a single case-control study.
‡Largest available health promotion campaign, in state of Victoria, Australia.
§Meta-analysis of available literature.
¶Burden of Disease study following standard WHO-CHOICE methods.
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RESEARCHTable 6| Costs, effects, and cost effectiveness of interventions to combat breast, cervical, and colorectal cancer in WHO sub-Saharan
African sub-region AfrE
Rank*
Cost effectiveness ratio Annual DALYs
averted per Annual cost
per capita
($Int)
Coverage
(%) Intervention Incremental Average
million
population
Breast cancer
8 2248 2248 313 0.68 50 BRE-6: Optimal programme (treatment of stages I–IV cancer, plus
biannual mammographic screening)
9 2261 2253 501 1.09 80 BRE-12: Optimal programme
10 2696 2323 595 1.34 95 BRE-18: Optimal programme
Cervical cancer
1 307 307 462 0.14 50 CVC-129: Smear test at age 40 (with lesion removal) + cancer
treatment
4 702 401 606 0.24 95 CVC-4: Treatment of invasive cancer (by surgery, chemotherapy,
and/or radiotherapy)
5 756 497 829 0.41 95 CVC-51: Smear test at age 40 + HPV vaccinations starting at age
12 at cost of US$0.60 per vaccine dose + cancer treatment
6 972 500 834 0.42 95 CVC-35: VIA at age 40 + HPV vaccine from age 12 at US$0.60 per
vaccine dose + cancer treatment
7 1675 550 872 0.48 95 CVC-49: VIA at ages 35, 40, 45 + HPV vaccine from age 12 at
US$0.60 per vaccine dose+ cancer treatment
12 3906 772 934 0.72 95 CVC-37: Smear test every five years for ages 20–65 + HPV vaccine
from age 12 at US$0.60 per vaccine dose+ cancer treatment
14 12 425 970 950 0.92 95 CVC-34: Smear test every three years for ages 20–65 + HPV
vaccine from age 12 at US$0.60 per vaccine dose+ cancer treatment
15 13 705 1048 956 1.00 95 CVC-43: Smear test every five years for ages 20–30 then smear
test with HPV vaccination every five years for ages 30–65 + HPV
vaccine from age 12 at US$0.60 per vaccine dose + cancer
treatment
17 27 139 1456 971 1.41 95 CVC-33: Annual smear test for ages 20–65 + HPV vaccine from
age 12 at US$0.60 per vaccine dose+ cancer treatment
18 100 075 2773 984 2.73 95 CVC-39: Annual smear test for ages 20–30 + then annual smear
test with HPV vaccination every five years for ages 30–65 + HPV
vaccine from age 12 at US$0.60 per vaccine dose+ cancer treatment
Colorectal cancer
2 336 336 792 0.27 80 CRC-35: Cancer treatment (by surgery, chemotherapy, and/or
radiotherapy)
3 337 336 1031 0.35 95 CRC-10: Cancer treatment
11 3630 585 1115 0.65 95 CRC-18: Colonoscopy at age 50 (with surgical removal of polyps)
+ cancer treatment
13 9598 766 1138 0.87 95 CRC-14: Colonoscopy screening every 10 years + cancer treatment
16 15 548 952 1153 1.10 95 CRC-15: Annual faecal occult blood test + sigmoidoscopy every 5
years (with surgical removal of polyps) + cancer treatment
HPV=human papillomavirus, VIA=visual inspection with acetic acid.
*Rank ordered on the basis of incremental cost effectiveness ratios.
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RESEARCHTable 7| Costs, effects, and cost effectiveness of interventions to combat breast, cervical, and colorectal cancer in WHO South East Asian
sub-region SearD
Rank*
Cost effectiveness ratio Annual DALYs
averted per Annual cost
per capita
($Int)
Coverage
(%) Intervention Incremental Average
million
population
Breast cancer
8 4338 4338 201 0.87 50 BRE-6: Optimal programme (treatment of stages I–IV cancer plus
biannual mammographic screening)
9 4401 4362 321 1.40 80 BRE-12: Optimal programme
10 4596 4399 381 1.68 95 BRE-18: Optimal programme
Cervical cancer
1 142 142 1327 0.19 50 CVC-129: Smear test at age 40 (with lesion removal) + cancer
treatment
3 477 182 1507 0.27 95 CVC-4: Treatment of invasive cancer by surgery, chemotherapy,
and/or radiotherapy
4 757 264 1755 0.46 95 CVC-23: Smear test at age 40 + cancer treatment
5 1240 269 1765 0.48 95 CVC-7: VIA at age 40 (with lesion removal) + cancer treatment
6 1719 294 1796 0.53 95 CVC-21: VIA at ages 35, 40, and 45 (with lesion removal) + cancer
treatment
7 2886 303 1803 0.55 95 CVC-17: Smear test at ages 35, 40, and 45 (with lesion removal)
+ cancer treatment
13 16 051 467 1822 0.85 95 CVC-34: Triennial smear test for ages 20–65 + HPV vaccinations
starting at age 12 at cost of US$0.60 per vaccine dose+ cancer
treatment
15 36 764 770 1837 1.41 95 CVC-41: Triennial smear test for ages 20–30 then triennial smear
test with HPV vaccination for ages 30–65+ HPV vaccinations
starting at age 12 at cost of US$0.60 per vaccine dose + cancer
treatment
17 81 629 1493 1854 2.77 95 CVC-39: Annual smear test for ages 20–30 then annual smear
test with HPV vaccination for ages 30–65+ HPV vaccinations
starting at age 12 at cost of US$0.60 per vaccine dose + cancer
treatment
Colorectal cancer
2 362 362 868 0.31 95 CRC-10: Cancer treatment by surgery, chemotherapy, and/or
radiotherapy
11 8291 574 891 0.51 95 CRC-17: Sigmoidoscopy at age 50 (with removal of polyps) +
cancer treatment
12 9318 794 914 0.73 95 CRC-18: Colonoscopy at age 50 (with removal of polyps) + cancer
treatment
14 28 017 1124 926 1.04 95 CRC-14: Colonoscopy screening every 10 years + cancer
treatment
16 42 940 1735 939 1.63 95 CRC-15: Annual faecal occult blood test + sigmoidoscopy every
5 years (with surgical removal of polyps) + cancer treatment
VIA=visual inspection with acetic acid, HPV=human papillomavirus.
*Rank ordered on the basis of incremental cost effectiveness ratios.
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RESEARCHFigures
Fig 1 Incremental cost and cost effectiveness of interventions to combat breast, cervical, and colorectal cancer in WHO
sub-Saharan African sub-region AfrE. See table 6⇓ for explanation of intervention codes
Fig 2 Incremental cost and cost effectiveness of interventions to combat breast, cervical, and colorectal cancer in WHO
South East Asian sub-region SearD. See table 7⇓ for explanation of intervention codes
Fig 3 Probabilistic uncertainty analysis of interventions to breast, cervical and colorectal cancer in WHO sub-Saharan
African sub-region Afr-E. See table 6⇓ for explanation of intervention codes
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RESEARCHFig 4 Probabilistic uncertainty analysis of interventions to breast, cervical and colorectal cancer in WHO South East Asian
sub-region Sear-D. See table 7⇓ for explanation of intervention codes
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